ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Improving Tailored Treatment Plans in HR+ and HER2- Early Breast Cancer
Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans. Inย an abstractย presented at theย 2024 San Antonio Breast Cancer Symposium, researchers used genomic profiling in Read More
Healthcare Tech Outlook Named Agendia as One of the Top 10 Precision Oncology Solutions Providers in 2024
We are happy to announce Agendia has been named one of the Top 10 Precision Oncology Solutions Providers in 2024. Agendia is proud to be a part of the precision medicine movement with our Read More
What Is Neoadjuvant Chemotherapy?
If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More
What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Breast Cancer Patients?
A conversation with Agendia CMO William Audeh, MD More than 17,000 patients have enrolled in Agendiaโs FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or Read More
News
Media Releases
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrintยฎ as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrintยฎ in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancerย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 11, 2024 โ Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, confirms results from NSABP B-42 demonstrating MammaPrint is predictive of extended endocrine therapy benefit IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 2, 2024 โ Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ expanding clinical utility to optimize treatment selection. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ November 25, 2024 โ Agendiaยฎ, Inc., announced today that new data on its Read More